Announcement: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Medical illustration showing gene editing targeting PCSK9 for cholesterol reduction
Eli Lilly's experimental gene-editing therapy VERV-102 achieved a 62% reduction in cholesterol levels at the highest dose in Phase 1 clinical trials. The single-dose treatment targets the PCSK9 gene to potentially provide permanent cholesterol control. โ€” Photo by Supplements On Demand on Pexels (Pexels License)
1 min read|33 words

๐Ÿงฌ BREAKTHROUGH: Eli Lilly's gene-editing therapy cuts cholesterol by 62% with a single dose! VERV-102 targets the PCSK9 gene for potentially permanent treatment. Could revolutionize cardiovascular care.

Read the full article on GMJ Newsroom โ†’

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper โ†’

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript โ†’
Ebola Bundibugyo outbreak in DRC triggers infodemic surge, with misinformation undermining public health response

Official confirmation of Ebola Bundibugyo in the DRC on 15 May 2026…

UK and US Regulators Launch Joint Liaison Programme to Strengthen Drug Approval Coordination

The UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food…

Cancer mortality gap widens: wealthy urban areas see steep declines while rural regions lag behind

Cancer mortality in the US has dropped steeply since 1991, but the…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript โ†’

You Might Also Like